NCT00635778View on ClinicalTrials.gov

A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 7, 2006

Primary Completion Date

November 5, 2008

Study Completion Date

November 5, 2008

Conditions
Advanced Solid Tumors
Interventions
DRUG

dalotuzumab

Administered as an IV infusion over one to two hours

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00635778 - A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) | Biotech Hunter | Biotech Hunter